pre-ipo
Stage
About
Taysha Gene Therapies is a clinical-stage company developing AAV-based gene therapies targeting monogenic central nervous system diseases, with lead candidates for GM2 gangliosidosis, Rett syndrome, and CLN1.
Explore Taysha Gene Therapies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.